查尔斯河实验室(CRL)近期股价在美股盘中出现大涨5.33%的行情。引发这一利好的主要原因如下:
公司最新公布的财报表现抢眼,旗下药物发现与开发服务业务持续增长。数据显示,公司年营收达40.5亿美元,净利润1030万美元,每股收益0.2美元。综合毛利率近30%,抵御通胀影响较为出色。
分析师看好公司前景,多家机构给予买入或持有评级。公司储备丰富的研发产品管线,在动物实验模型、药物发现等领域处于领先地位,有望持续受益医药研发长期投入增长。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.